title: Peroxidation of LDL from combined-hyperlipidemic male smokers supplied with omega-3 fatty acids and antioxidants.
abstract: The effects of marine omega-3 polyunsaturated fatty acids (FAs) and antioxidants on the oxidative modification of LDL were studied in a randomized, double-blind, placebo-controlled trial. Male smokers (n = 41) with combined hyperlipidemia were allocated to one of four groups receiving supplementation with omega-3 FAs (5 g eicosapentaenoic acid and docosahexaenoic acid per day), antioxidants (75 mg vitamin E, 150 mg vitamin C, 15 mg beta-carotene, and 30 mg coenzyme Q10 per day), both omega-3 FAs and antioxidants, or control oils. LDL and human mononuclear cells were isolated from the patients at baseline and after 6 weeks of supplementation. LDL was subjected to cell-mediated oxidation by the patients' own mononuclear cells, as well as to Cu(2+)-catalyzed and 2,2'-azobis-(2-amidinopropane hydrochloride) (AAPH)-initiated oxidation. Extent of LDL modification was measured as lag time, the formation rate of conjugated dienes (CDs), the maximum amount of CDs formed, formation of lipid peroxides, and the relative electrophoretic mobility of LDL on agarose gels. Dietary supplementation with omega-3 FAs increased the concentration of total omega-3 FAs in LDL and reduced the concentration of vitamin E in serum. The omega-3 FA-enriched LDL particles were not more susceptible to Cu(2+)-catalyzed, AAPH-initiated, or autologous cell-mediated oxidation than control LDL. In fact, enrichment with omega-3 FAs significantly reduced the formation rate of CDs when LDL was subjected to AAPH-induced oxidation. Supplementation with moderate amounts of antioxidants significantly increased the concentration of vitamin E in serum and increased the resistance of LDL to undergo Cu(2+)-catalyzed oxidation, measured as increased lag time, reduced formation of lipid peroxides, and reduced relative electrophoretic mobility compared with control LDL. Supplementation with omega-3 FAs/antioxidants showed oxidizability of LDL similar to that of control LDL and omega-3 FA-enriched LDL. In conclusion, omega-3 FAs neither rendered the LDL particles more susceptible to undergo in vitro oxidation nor influenced mononuclear cells' ability to oxidize autologous LDL, whereas moderate amounts of antioxidants protected LDL against oxidative modification.
authors.affiliation: Institute for Nutrition Research, University of Oslo, Norway.
authors.forename: I R
authors.initials: IR
authors.lastname: Brude
authors.forename: C A
authors.initials: CA
authors.lastname: Drevon
authors.forename: I
authors.initials: I
authors.lastname: Hjermann
authors.forename: I
authors.initials: I
authors.lastname: Seljeflot
authors.forename: S
authors.initials: S
authors.lastname: Lund-Katz
authors.forename: K
authors.initials: K
authors.lastname: Saarem
authors.forename: B
authors.initials: B
authors.lastname: Sandstad
authors.forename: K
authors.initials: K
authors.lastname: Solvoll
authors.forename: B
authors.initials: B
authors.lastname: Halvorsen
authors.forename: H
authors.initials: H
authors.lastname: Arnesen
authors.forename: M S
authors.initials: MS
authors.lastname: Nenseter
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000975:Antioxidants / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D001205:Ascorbic Acid / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use; D003067:Coenzymes; D003300:Copper / Q000494:pharmacology; D004311:Double-Blind Method; D004357:Drug Synergism; D015525:Fatty Acids, Omega-3 / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology* / Q000627:therapeutic use; D005395:Fish Oils / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D006950:Hyperlipidemia, Familial Combined / Q000097:blood* / Q000188:drug therapy; D007963:Leukocytes, Mononuclear / Q000187:drug effects / Q000378:metabolism; D015227:Lipid Peroxidation / Q000187:drug effects*; D008077:Lipoproteins, LDL / Q000097:blood*; D008297:Male; D008875:Middle Aged; D016877:Oxidants / Q000494:pharmacology; D010084:Oxidation-Reduction; D010316:Particle Size; D010743:Phospholipids / Q000097:blood / Q000737:chemistry; D012907:Smoking / Q000097:blood*; D055672:Static Electricity; D014451:Ubiquinone / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use; D014810:Vitamin E / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use; D019207:beta Carotene / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D000975:Antioxidants; D003067:Coenzymes; D015525:Fatty Acids, Omega-3; D005395:Fish Oils; D008077:Lipoproteins, LDL; D016877:Oxidants; D010743:Phospholipids; C099252:oxidized low density lipoprotein; D019207:beta Carotene; D014451:Ubiquinone; D014810:Vitamin E; D003300:Copper; C024989:coenzyme Q10; D001205:Ascorbic Acid